SAN FRANCISCO, Dec. 17 - Invitrogen will join 12 other companies that will be added to the Nasdaq-100 Index next Monday.
The Nasdaq-100, the 100 largest non-financial stocks on the Nasdaq Stock Market, is re-ranked every December. The rankings are based on a company's market capitalization, computed using closing prices as of October 31 and the publicly reported total shares outstanding as of November 30.
At the time of ranking, Invitrogen's market capitalization was $3.2 billion, according to Nasdaq.
"Our appointment to the Index is a testament to Invitrogen's rapid growth and consistent performance throughout its history and since becoming a public company in 1999," Lyle Turner, CEO of Invitrogen, said in a statement.
Eight of this year's 13 additions to the Nasdaq-100 are life science-oriented companies. Corporations listed in the Index are included in the Nasdaq-100 Index Tracking Stock, the world's most actively traded exchange-traded fund, according to Nasdaq.
In early December, Invitrogen, based in